1
|
Malya IY, Wu J, Harada E, Toda M, D'Alessandro-Gabazza CN, Yasuma T, Gabazza EC, Choi JH, Hirai H, Kawagishi H. Plant growth regulators and Axl and immune checkpoint inhibitors from the edible mushroom Leucopaxillus giganteus. Biosci Biotechnol Biochem 2020; 84:1332-1338. [PMID: 32200702 DOI: 10.1080/09168451.2020.1743170] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Accepted: 03/12/2020] [Indexed: 02/01/2023]
Abstract
A novel compound, (R)-4-ethoxy-2-hydroxy-4-oxobutanoic acid (1), and six known compounds (2-7) were isolated from the fruiting bodies of the wild edible mushroom Leucopaxillus giganteus. The planar structure of 1 was determined by the interpretation of spectroscopic data analysis. The absolute configuration of 1 was determined by comparing specific rotation of the synthetic compounds. In the plant regulatory assay, the isolated compounds (1-7) and the chemically prepared compounds (8-10) were evaluated their biological activity against the lettuce (Lactuca sativa) growth. Compounds 1 and 3-10 showed the significant regulatory activity of lettuce growth. 1 showed the strongest inhibition activity among the all the compounds tested. In the lung cancer assay, all the compounds were assessed the mRNA expression of Axl and immune checkpoints (PD-L1, PD-L2) in the human A549 alveolar epithelial cell line by RT-PCR. Compounds 1-10 showed significant inhibition activity against Axl and/or immune checkpoint.
Collapse
Affiliation(s)
| | - Jing Wu
- Research Institute of Green Science and Technology, Shizuoka University , Shizuoka, Japan
| | - Etsuko Harada
- Department of Forest and Environmental Science, Miyazaki University , Miyazaki, Japan
| | - Masaaki Toda
- Department of Immunology, Mie University Graduate School of Medicine , Mie, Japan
| | | | - Taro Yasuma
- Department of Immunology, Mie University Graduate School of Medicine , Mie, Japan
| | - Esteban C Gabazza
- Department of Immunology, Mie University Graduate School of Medicine , Mie, Japan
| | - Jae-Hoon Choi
- Research Institute of Green Science and Technology, Shizuoka University , Shizuoka, Japan
- Graduate School of Integrated Science and Technology, Shizuoka University , Shizuoka, Japan
| | - Hirofumi Hirai
- Research Institute of Green Science and Technology, Shizuoka University , Shizuoka, Japan
- Graduate School of Integrated Science and Technology, Shizuoka University , Shizuoka, Japan
| | - Hirokazu Kawagishi
- Graduate School of Science and Technology, Shizuoka University , Shizuoka, Japan
- Research Institute of Green Science and Technology, Shizuoka University , Shizuoka, Japan
- Graduate School of Integrated Science and Technology, Shizuoka University , Shizuoka, Japan
| |
Collapse
|
2
|
Phan CW, Wang JK, Cheah SC, Naidu M, David P, Sabaratnam V. A review on the nucleic acid constituents in mushrooms: nucleobases, nucleosides and nucleotides. Crit Rev Biotechnol 2017; 38:762-777. [PMID: 29124970 DOI: 10.1080/07388551.2017.1399102] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Mushrooms have become increasingly important as a reliable food source. They have also been recognized as an important source of bioactive compounds of high nutritional and medicinal values. The nucleobases, nucleosides and nucleotides found in mushrooms play important roles in the regulation of various physiological processes in the human body via the purinergic and/or pyrimidine receptors. Cordycepin, a 3'-deoxyadenosine found in Cordyceps sinensis has received much attention as it possesses many medicinal values including anticancer properties. In this review, we provide a broad overview of the distribution of purine nucleobases (adenine and guanine); pyrimidine nucleobases (cytosine, uracil, and thymine); nucleosides (uridine, guanosine, adenosine and cytidine); as well as novel nucleosides/tides in edible and nonedible mushrooms. This review also discusses the latest research focusing on the successes, challenges, and future perspectives of the analytical methods used to determine nucleic acid constituents in mushrooms. Besides, the exotic taste and flavor of edible mushrooms are attributed to several nonvolatile and water-soluble substances, including the 5'-nucleotides. Therefore, we also discuss the total flavor 5'-nucleotides: 5'-guanosine monophosphate (5'-GMP), 5'-inosine monophosphate (5'-IMP), and 5'-xanthosine monophosphate (5'-XMP) in edible mushrooms.
Collapse
Affiliation(s)
- Chia-Wei Phan
- a Mushroom Research Centre , University of Malaya , Kuala Lumpur , Malaysia.,b Department of Anatomy, Faculty of Medicine , University of Malaya , Kuala Lumpur , Malaysia
| | - Joon-Keong Wang
- c Faculty of Medicine and Health Sciences , UCSI University , Kuala Lumpur , Malaysia
| | - Shiau-Chuen Cheah
- c Faculty of Medicine and Health Sciences , UCSI University , Kuala Lumpur , Malaysia
| | - Murali Naidu
- a Mushroom Research Centre , University of Malaya , Kuala Lumpur , Malaysia.,b Department of Anatomy, Faculty of Medicine , University of Malaya , Kuala Lumpur , Malaysia
| | - Pamela David
- a Mushroom Research Centre , University of Malaya , Kuala Lumpur , Malaysia.,b Department of Anatomy, Faculty of Medicine , University of Malaya , Kuala Lumpur , Malaysia
| | - Vikineswary Sabaratnam
- a Mushroom Research Centre , University of Malaya , Kuala Lumpur , Malaysia.,d Institute of Biological Sciences, Faculty of Science , University of Malaya , Kuala Lumpur , Malaysia
| |
Collapse
|
3
|
Friesen WJ, Trotta CR, Tomizawa Y, Zhuo J, Johnson B, Sierra J, Roy B, Weetall M, Hedrick J, Sheedy J, Takasugi J, Moon YC, Babu S, Baiazitov R, Leszyk JD, Davis TW, Colacino JM, Peltz SW, Welch EM. The nucleoside analog clitocine is a potent and efficacious readthrough agent. RNA (NEW YORK, N.Y.) 2017; 23:567-577. [PMID: 28096517 PMCID: PMC5340919 DOI: 10.1261/rna.060236.116] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Accepted: 01/05/2017] [Indexed: 06/01/2023]
Abstract
Nonsense mutations resulting in a premature stop codon in an open reading frame occur in critical tumor suppressor genes in a large number of the most common forms of cancers and are known to cause or contribute to the progression of disease. Low molecular weight compounds that induce readthrough of nonsense mutations offer a new means of treating patients with genetic disorders or cancers resulting from nonsense mutations. We have identified the nucleoside analog clitocine as a potent and efficacious suppressor of nonsense mutations. We determined that incorporation of clitocine into RNA during transcription is a prerequisite for its readthrough activity; the presence of clitocine in the third position of a premature stop codon directly induces readthrough. We demonstrate that clitocine can induce the production of p53 protein in cells harboring p53 nonsense-mutated alleles. In these cells, clitocine restored production of full-length and functional p53 as evidenced by induced transcriptional activation of downstream p53 target genes, progression of cells into apoptosis, and impeded growth of nonsense-containing human ovarian cancer tumors in xenograft tumor models. Thus, clitocine induces readthrough of nonsense mutations by a previously undescribed mechanism and represents a novel therapeutic modality to treat cancers and genetic diseases caused by nonsense mutations.
Collapse
Affiliation(s)
| | | | - Yuki Tomizawa
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | - Jin Zhuo
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | - Briana Johnson
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | - Jairo Sierra
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | - Bijoyita Roy
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | - Marla Weetall
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | - Jean Hedrick
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | | | - James Takasugi
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | | | - Suresh Babu
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | - Ramil Baiazitov
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | - John D Leszyk
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01655-0122, USA
| | - Thomas W Davis
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | | | - Stuart W Peltz
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| | - Ellen M Welch
- PTC Therapeutics, Inc., South Plainfield, New Jersey 07080, USA
| |
Collapse
|
4
|
Liu MM, Mei Q, Zhang YX, Bai P, Guo XH. Palladium-catalyzed amination of chloro-substituted 5-nitropyrimidines with amines. CHINESE CHEM LETT 2017. [DOI: 10.1016/j.cclet.2016.11.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
5
|
Sun JG, Ruan F, Zeng XL, Xiang J, Li X, Wu P, Fung KP, Liu FY. Clitocine potentiates TRAIL-mediated apoptosis in human colon cancer cells by promoting Mcl-1 degradation. Apoptosis 2016; 21:1144-57. [DOI: 10.1007/s10495-016-1273-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Mukherjee N, Schwan JV, Fujita M, Norris DA, Shellman YG. Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol 2015; 135:2155-2161. [PMID: 25947358 PMCID: PMC4537369 DOI: 10.1038/jid.2015.145] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Revised: 03/19/2015] [Accepted: 03/24/2015] [Indexed: 12/18/2022]
Abstract
For the first time new treatments in melanoma have produced significant responses in advanced diseases, but 30-90% of melanoma patients do not respond or eventually relapse after the initial response to the current treatments. The resistance of these melanomas is likely due to tumor heterogeneity, which may be explained by models such as the stochastic, hierarchical, and phenotype-switching models. This review will discuss the recent advancements in targeting BCL-2 family members for cancer treatments, and how this approach can be applied as an alternative option to combat melanoma, and overcome melanoma relapse or resistance in current treatment regimens.
Collapse
Affiliation(s)
- Nabanita Mukherjee
- Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Josianna V Schwan
- Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Mayumi Fujita
- Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; Department of Veterans Affairs Medical Center, Dermatology Section, Denver, Colorado, USA
| | - David A Norris
- Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; Department of Veterans Affairs Medical Center, Dermatology Section, Denver, Colorado, USA
| | - Yiqun G Shellman
- Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
| |
Collapse
|
7
|
Leclerc GJ, DeSalvo J, Du J, Gao N, Leclerc GM, Lehrman MA, Lampidis TJ, Barredo JC. Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress. Leuk Res 2015; 39:S0145-2126(15)30360-X. [PMID: 26346348 PMCID: PMC4783293 DOI: 10.1016/j.leukres.2015.08.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Revised: 07/21/2015] [Accepted: 08/15/2015] [Indexed: 12/31/2022]
Abstract
BCR-ABL positive (+) acute lymphoblastic leukemia (ALL) accounts for ∼30% of cases of ALL. We recently demonstrated that 2-deoxy-d-glucose (2-DG), a dual energy (glycolysis inhibition) and ER-stress (N-linked-glycosylation inhibition) inducer, leads to cell death in ALL via ER-stress/UPR-mediated apoptosis. Among ALL subtypes, BCR-ABL+ ALL cells exhibited the highest sensitivity to 2-DG suggesting BCR-ABL expression may be linked to this increased vulnerability. To confirm the role of BCR-ABL, we constructed a NALM6/BCR-ABL stable cell line and found significant increase in 2-DG-induced apoptosis compared to control. We found that Mcl-1 was downregulated by agents inducing ER-stress and Mcl-1 levels correlated with ALL sensitivity. In addition, we showed that Mcl-1 expression is positively regulated by the MEK/ERK pathway, dependent on BCR-ABL, and further downregulated by combining ER-stressors with TKIs. We determined that energy/ER stressors led to translational repression of Mcl-1 via the AMPK/mTOR and UPR/PERK/eIF2α pathways. Taken together, our data indicate that BCR-ABL+ ALL exhibits heightened sensitivity to induction of energy and ER-stress through inhibition of the MEK/ERK pathway, and translational repression of Mcl-1 expression via AMPK/mTOR and UPR/PERK/eIF2α pathways. This study supports further consideration of strategies combining energy/ER-stress inducers with BCR-ABL TKIs for future clinical translation in BCR-ABL+ ALL patients.
Collapse
Affiliation(s)
- Guy J Leclerc
- Department of Pediatrics, Division of Hematology and Oncology, University of Miami Miller School of Medicine, Miami, FL 33101, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33101, USA
| | - Joanna DeSalvo
- Department of Pediatrics, Division of Hematology and Oncology, University of Miami Miller School of Medicine, Miami, FL 33101, USA
| | - Jianfeng Du
- Department of Pediatrics, Division of Hematology and Oncology, University of Miami Miller School of Medicine, Miami, FL 33101, USA
| | - Ningguo Gao
- Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
| | - Gilles M Leclerc
- Department of Pediatrics, Division of Hematology and Oncology, University of Miami Miller School of Medicine, Miami, FL 33101, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33101, USA
| | - Mark A Lehrman
- Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
| | - Theodore J Lampidis
- Department of Cell Biology and Anatomy, University of Miami Miller School of Medicine, Miami, FL 33101, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33101, USA
| | - Julio C Barredo
- Department of Pediatrics, Division of Hematology and Oncology, University of Miami Miller School of Medicine, Miami, FL 33101, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33101, USA; Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33101, USA; Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
| |
Collapse
|
8
|
Zhu X, Zhang K, Wang Q, Chen S, Gou Y, Cui Y, Li Q. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin. Med Oncol 2015; 32:133. [PMID: 25796504 DOI: 10.1007/s12032-015-0588-9] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Accepted: 03/14/2015] [Indexed: 01/25/2023]
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses multidrug resistance (MDR) and induces apoptosis in MDR gastric carcinoma cells. In our previous study, cisplatin proved to be a sensitizing agent for TRAIL. To study the synergistic effects of cisplatin and TRAIL, we investigated the mechanism by which TRAIL reverses multidrug resistance, the role of c-myc in modulating the death receptors DR4 and DR5 and the relationship between cisplatin and cytochrome c (cyt c) release in SGC7901/VCR and SGC7901/DDP cells. We found that after treatment with TRAIL, the DNA-PKcs/Akt/GSK-3β pathway, which is positively correlated with the levels of MDR1 and MRP1, was significantly inhibited and that this tendency can be abolished by Z-DEVD-FMK (a specific caspase 3 inhibitor). We also found that suppression of c-myc by siRNA reduced the expression of DR4 and DR5 and that transfection with a pAVV-c-myc expression vector increased the expression of DR4 and DR5. Moreover, cisplatin increased the expression of c-myc in the presence of TRAIL, and there is a clear increase in cyt c release from mitochondria with the increasing concentrations of cisplatin. Meanwhile, the intrinsic death receptor pathway of caspase 9, as well as the common intrinsic and extrinsic downstream target, caspase 3, was potently activated by the release of cyt c. Together, we conclude that in TRAIL-treated MDR gastric carcinoma cells, cisplatin induces the death receptors DR4 and DR5 through the up-regulation of c-myc and strengthens the activation of caspases via promoting the release of cyt c. These effects would then be responsible for the TRAIL sensitization effect of cisplatin.
Collapse
Affiliation(s)
- Xingchao Zhu
- Department of Gastroenterology, Affiliated Provincial Hospital of Anhui Medical University, 17 Lu Jiang Road, Hefei, 230001, Anhui Province, China
| | | | | | | | | | | | | |
Collapse
|
9
|
Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak. Cancer Lett 2014; 355:253-63. [DOI: 10.1016/j.canlet.2014.09.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2014] [Revised: 09/12/2014] [Accepted: 09/13/2014] [Indexed: 12/18/2022]
|